Venthera, Inc.

1:30 PM - 1:45 PM (PDT), Monday, June 13, 2022
Venthera, an affiliate of BridgeBio Pharma, is a biotechnology company focused on developing therapeutics for the treatment of venous and lymphatic malformations, congenital conditions that are driven by activating mutations of the PI3K signaling pathway. We aim to develop a safe and effective treatment for these painful disorders as quickly and safely as possible.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
VT30 Topical Gel AKA BBP 681
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Venthera, Inc.